Canavan Disease clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • AAV9 Gene Therapy in Participants With Canavan Disease

    open to eligible people ages up to 30 months

    The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.

    at UCSF

Our lead scientists for Canavan Disease research studies include .

Last updated: